Clinical Trials

SAN DIEGO — A novel, oral therapeutic for treatment of migraine was safe and well-tolerated in single ascending doses in a cohort of healthy adults, according to a speaker at the American Headache Society Annual Scientific Meeting.

The American Cancer Society has launched VOICES of Black Women, a large long-term population study of cancer risk and outcomes among Black women in the United States.

Newly released data from the open-label extension of the FIREFISH study confirmed sustained safety and efficacy of Evrysdi in children with type 1 spinal muscular atrophy over 5 years.

There is a wide capacity for clinical research in India. We have a large, diverse population, large urban hospitals and well-trained specialists. However, for multiple reasons, this capacity is not fully exploited.

I have shared my thoughts on diversity, equity, inclusion and social justice in the U.S. regarding racial distribution in ophthalmology in three prior Lindstrom’s Perspectives.

Due to a complex interplay of genetic, lifestyle and environmental factors, as well as access to health care, the burden for advanced eye disease is highest among racial and ethnic minority groups.

Azura Ophthalmics announced that the first patient has been enrolled in the phase 3 ASTRO study of AZR-MD-001 for patients with clinical signs and symptoms of meibomian gland dysfunction.

SAN DIEGO — Using race-neutral equations to determine eligibility for COPD clinical trials may lead to higher percentages of Black patients enrolled, according to a poster presented at the American Thoracic Society International Conference.

Annexon Biosciences has announced positive topline results from a phase 3, randomized placebo-controlled clinical trial examining an investigational monoclonal antibody in those with Guillain-Barré syndrome.

Takeda has reported positive results from a phase 2b clinical trial of an investigational, oral orexin receptor agonist for narcolepsy type 1.